U.S. health start-ups profiting from shortages of popular anti-obesity drugs are facing questions over the sustainability of their new revenue streams, Oliver Barnes of The Financial Times reports. Telehealth companies, such as Hims & Hers (HIMS), have cornered the market in cheaper alternatives to mainstream jabs, serving customers unable to get their hands on originals, such as Novo Nordisk’s (NVO) Wegovy and Eli Lilly’s (LLY) Zepbound. U.S. law stipulates copycat drugs can only be manufactured in bulk when the branded originals are officially designated as being in short supply.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HIMS:
- Viking Therapeutics selloff on Zepbound news an opportunity, says Truist
- Him & Hers tumbles as Lilly slashes prices on lowest doses of weight loss drug
- Morning Movers: Paramount slides as Bronfman drops bid
- Citi says Lilly Zepbound offering ‘shot across the bow’ for compounders
- Hims & Hers slips after Lilly says discount Zepbound single-dose vials available